請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53604完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 胡文聰 | |
| dc.contributor.author | Po-Kang Chang | en |
| dc.contributor.author | 張博綱 | zh_TW |
| dc.date.accessioned | 2021-06-16T02:26:15Z | - |
| dc.date.available | 2025-12-31 | |
| dc.date.copyright | 2015-08-07 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-05 | |
| dc.identifier.citation | [1] K. Pantel, R. H. Brakenhoff and B. Brandt. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer, 8(5):329–340, May 2008.
[2] K. Pantel et al. Cancer micrometastases. Nature Reviews Clinical Oncology, 6(9):339–351, Jun. 2009. [3] W. Janni et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a european pooled analysis. Clinical Cancer Research, 17(9):2967–2976, May 2011. [4] K. Pantel and C. Alix-Panabieres. Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Research, 73(21):6384–6388, Dec. 2013. [5] C. Alix-Panabieres and J. Y. Pierga. Circulating tumor cells : Liquid biopsy. Cancer Research, 101(1):17–23, Jan. 2014. [6] M. Cristofanilli et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine, 351(8):17–23, Aug. 2004. [7] F. Nole et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. New Eng- land Journal of Medicine, 19(5):891–897, May 2008. [8] F. C. Bidard et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, 15(4):406–414, Apr. 2014. [9] M. S. Wicha et al. Circulating tumor cells: Not all detected cells are bad and not all bad cells are detected. Journal of Clinical Oncology, 29(12):1508–1511, Apr. 2011. [10] M. Yu et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339(6119):580–584, Feb. 2013. [11] M. G. Krebs et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nature Review Clinical Oncology, 11(3):129–144, Mar. 2014. [12] S. Riethdorf et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the cellsearch system. American Association for Cancer Research, 13(3):920–928, Feb. 2007. [13] A. H. Talasaz et al., editor. High-throughput genetic and expression analy- sis of circulating tumor cells, volume 51 of 277. Proceedings of the American Association for Cancer Research Annual Meeting, 2010. [14] A. A. Powell et al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. Plos One, 7(5), May 2012. [15] W. Harb et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qpcr assay. Translational Oncology, 6(5): 528–538, Oct. 2013. [16] S. Nagrath et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature, 450(7173):1235–U10, Oct. 2007. [17] S. L. Stott et al. Isolation of circulating tumor cells using a microvortex- generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America, 107(43):18392–18397, Oct. 2010. [18] U. Dharmasiri et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Proceedings of the National Academy of Sciences of the United States of America, 83(6):2301–2309, Mar. 2011. [19] R. Y. J. Huang et al. Early events in cell adhesion and polarity during epithelial- mesenchymal transition. Journal of Cell Science, 125(19):4417–4422, Oct. 2012. [20] G. Vona et al. Isolation by size of epithelial tumor cells - a new method for the immunomorphological and molecular characterization of circulating tumor cells. American Journal of Pathology, 156(1):57–63, Jan. 2000. [21] S. J. Tan et al. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosensors & Bioelectronics, 26(4):1701–1705, Dec. 2010. [22] H. S. Moon et al. Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (moff) and dielectrophoresis (dep). Lab on a Chip, 11(6):1118–1125, 2011. [23] R. A. Harouaka et al. Circulating tumor cell enrichment based on physical properties. Jala, 18(6):455–468, Dec. 2013. [24] A. Boyum. Isolation of mononuclear cells and granulocytes from human blood - isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1g. Scandinavian Journal of Clinical & Laboratory Investigation, S21(97):77–89, 1968. [25] C. Daniel et al. High-recovery multiplex analysis of circulating tumor cells by density-based enrichment, automated platform immunofluorescence staining, and digital microscopy. In AACR, San Diego, CA, 2014. [26] C.-L. Chen et al. Separation and detection of rare cells in a microfluidic disk via negative selection. Lab on a chip, 11(3):474–483, Feb. 2011. [27] C.-L. Chen. Separation and Detection of Rare Cells in a Microfluidic Disk Platform. PhD thesis, National Taiwan University, 2010. [28] Y.-C. Pan. Detection of rare cells in a microfluidic disk system via positive selection. Master thesis, National Taiwan University, 2009. [29] C.-W. Yang. Enumeration of metastatic cancer cells from whole blood in a microfluidic lab-on-disk platform via online multi-fluorescence labeling and de- terministic vent valves. Master thesis, National Taiwan University, 2010. [30] W.-H.Lian.Isolationofmetastaticcancercellsfromwholebloodinacentrifugal microfluidic platform via density gradient. Master thesis, National Taiwan University, 2012. [31] W.-F. Hsu. Isolation and enrichment of circulating tumor cells from human peripheral blood using a chip disc microfluidic platform. Master thesis, National Taiwan University, July 2014. [32] M.-Z. Li. An automated, seamless microfluidic system for single cell isolation and retrieval from whole blood. Master thesis, National Taiwan University, July 2014. [33] W.-Y. Ma. dissertation. PhD thesis, National Taiwan University, 2015. [34] M. Banys-Paluchowski et al. Prognostic relevance of circulating tumor cells in molecular subtypes of breast cancer. Geburtshilfe Und Frauenheilkunde, 75(3): 1–11, Mar. 2015. [35] Klaus Pantel Catherine Alix-Panabieres. Circulating tumor cells: Liquid biopsy of cancer. Clinical Chemistry, 59(1):110–118, Jan. 2013. [36] Catherine Alix-Panabieres Natalia Bednarz-Knoll and Klaus Pantel. Clinical relevance and biology of circulating tumor cells. Breast Cancer Research, 13:228, 2011. [37] L. A. Martin N. Patani and M. Dowsett. Biomarkers for the clinical man- agement of breast cancer: International perspective. International Journal of Cancer, 133(1):1–13, Jul. 2013. [38] A. Babayan et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. Plos One, 8(9):11, Sep. 2013. [39] C. Paoletti et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor positive breast cancer. American Association for Cancer Research, Nov. 2014. [40] R. Sandhu et al. Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. Labmedicine, 41(6):364–372, Jun. 2010. [41] S. Dawood and M. Cristofanilli. Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies? Future Medicine, 2015. [42] M. Zhao et al. Imaging multiple biomarkers in captured rare cells by sequential immunostaining and photobleaching. Methods, 64(2):108–113, Dec. 2013. [43] P. G. Schiro et al. Sensitive and high-throughput isolation of rare cells from peripheral blood with ensemble-decision aliquot ranking. Angewandte Chemie- International Edition, 51(19):4618–4622, 2012. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53604 | - |
| dc.description.abstract | 根據 Globocan 2012 年統計,全球有將近 820 萬人死於癌症,而目 前認為癌症轉移與許多癌症患者的死亡有關。現今,從病人血液中取 出的循環腫瘤細胞已獲得許多關注,且被視為很有潛力能成為檢測癌 症的指標,如無惡化存活期(progression-free survival)和整體存活期(overall survival)皆有許多針對乳癌、前列腺癌與結腸直腸癌的臨床 試驗證實,因此研發了許多循環腫瘤細胞的純化與分離技術。然而, 由於循環腫瘤細胞之間的變異性極高,只有數量不足以在臨床應用上 提供足夠的資訊,因此針對循環腫瘤細胞做進一步的分析日趨重要。
本研究建構了一套整合現有細胞抓取系統的半自動化序列染色系 統,該系統重新設計整個染色過程,除了可獲得更正確的訊號,亦 可獲得循環腫瘤細胞更多的顯型,解決了多數實驗室的螢光顯微鏡 只有四個波段可觀察,且其中 PE 波段的訊號極有可能會有漏光現 象進而影響 FITC 的訊號之問題。此外,在辨別循環腫瘤細胞時需 要使用三個波段,導致只剩一個波段可用於進一步的分析。利用這 套系統,可以在四波段的螢光顯微鏡下獲得五個訊息,當中包含三 個辨別訊號以及兩個亞型訊號。實驗分析三種代表性細胞株 MCF-7、 AU565、MDA-MB-231 的特性後,相同總數而不同的混合比例去模擬 ER/HER2 亞型的情形。結果顯示該系統的回收率與染色效率與先前 的系統並沒有顯著差異,且 HER2 的表現相當穩定,然而 ER 會有 ±12.0% 的誤差。儘管如此,不同亞型的比例依然都可成功地預測與偵 測。藉由該多功能平台,我們提供了更多循環腫瘤細胞之亞型顯型訊 息,以利相關的後端研究。 | zh_TW |
| dc.description.abstract | According to Globocan, there were 8.2 million cancer deaths in 2012 worldwide, and metastasis was considered to be related to the death of many cancer patients. Nowadays circulating tumor cells (CTCs) obtained from blood samples has been considered as a promising indicator for prognosis such as progression-free survival (PFS) and overall survival (OS) of patients, and has been used and validated in many clinical trials in metastatic breast, prostate and colorectal cancers. Therefore, many technologies have been developed for CTCs enrichment and isolation. However, several studies show that CTC enumeration alone is not enough for clinical utility due to their high heterogeneity. Therefore, further analysis of enumerated CTCs has become increasingly important.
This work presents a semi-automated sequential staining system combined with a single cell retrieval system as a competent multi-functional platform. It redesigned the staining procedure in order to obtain clearer signals and get more information about the phenotype of CTCs. Since in most cases, laboratories have only four-channel-fluorescence microscopes, where PE signal is likely to interfere with FITC signal due to its light leakage problem. Moreover, three channels may be used to identify CTCs, and only one channel remains for further information. By using this system, we may obtain five fluorescent signals in a four-channel-fluorescence microscope for both CTC detection and its subtype identification. Experiments characterized MCF-7, AU565, and MDA-MB-231 and used total about 50 cells to simulate ER/HER2 subtypes with different ratio of cell lines. Results show that recovery rate and staining efficiency in sequential staining system has no significant differences to the disk system. Also, it indicates that the performances were good for HER2 expression, while about SD=12.0% for ER expression. The overall proportion of mixed subtypes were successfully predicted and detected. With this multi-functional platform, we were able to provide more information about the subtype expression and may offer further analyses on CTCs. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T02:26:15Z (GMT). No. of bitstreams: 1 ntu-104-R02543077-1.pdf: 4300073 bytes, checksum: 4614bb855d8c651aed9321157d0866a9 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 口試委員ﰃﰄ會審ﰅ定書 i
致謝 ii 中文摘ﰁ要 iii Abstract iv Contents vi List of Figures viii List of Tables ix 1 Introduction 1 1.1 Clinical relevance and development of circulating tumor cells . . . . . 1 1.2 Technologies of CTC enrichment and isolation . . . . . . . . . . . . . 3 1.3 Development of micro fluidic disk platform . . . . . . . . . . . . . . . 6 1.4 CTC subtypes............................... 7 2 Materials and methods 10 2.1 Technology of CTC retrieval system................... 10 2.1.1 Overview of total CTC retrieval system . . . . . . . . . . . . 10 2.1.2 Microfluidic disk platform for isolation and enrichment . . . . 11 2.1.3 Microcavity chip ......................... 15 2.2 Sequential staining system........................ 16 2.3 Experiment preparation ......................... 18 2.3.1 Celllines and cell culture .................... 18 2.3.2 Reagents ............................. 19 2.4 Transferring solution in chip....................... 21 2.4.1 Procedure of transferring solution in chip . . . . . . . . . . . 21 2.4.2 Immobilization characterization................. 22 2.5 Sequential staining ............................ 23 2.5.1 Procedure of sequential staining................. 23 2.5.2 Staining efficiency ........................ 25 2.5.3 Characteristics of celllines.................... 26 2.5.4 Mixed cell lines test without blood . . . . . . . . . . . . . . . 26 2.5.5 Mixed cell lines test in whole blood . . . . . . . . . . . . . . . 27 2.6 Cell detection and selection ....................... 28 3 Results and discussion 31 3.1 Immobilization characterization ..................... 31 3.2 Staining efficiency............................. 33 3.3 Characteristics of cell lines........................ 35 3.4 Results of mixed cell lines ........................ 39 3.4.1 Results of mixed cell lines test without blood . . . . . . . . . 39 3.4.2 Results of mixed cell lines test in whole blood . . . . . . . . . 42 4 Conclusions 45 References47 | |
| dc.language.iso | en | |
| dc.subject | 序列染色 | zh_TW |
| dc.subject | 循環腫瘤細胞 | zh_TW |
| dc.subject | 亞型分選 | zh_TW |
| dc.subject | sequential staining | en |
| dc.subject | Circulating tumor cells | en |
| dc.subject | subtype | en |
| dc.title | 序列染色法應用於循環腫瘤細胞之分選 | zh_TW |
| dc.title | Subtyping of Circulating Tumor Cells Using a Sequential Staining Method | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李雨,許聿翔 | |
| dc.subject.keyword | 循環腫瘤細胞,亞型分選,序列染色, | zh_TW |
| dc.subject.keyword | Circulating tumor cells,subtype,sequential staining, | en |
| dc.relation.page | 52 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-08-05 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 應用力學研究所 | zh_TW |
| 顯示於系所單位： | 應用力學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 未授權公開取用 | 4.2 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。